Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammationGlobeNewsWire • 04/07/22
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 InflammationPRNewsWire • 04/07/22
Regeneron Builds On Retinal Disease Expertise Via Gene Therapy Pact With ViGeneronBenzinga • 04/06/22
Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022PRNewsWire • 04/05/22
Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitisGlobeNewsWire • 04/04/22
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic EsophagitisPRNewsWire • 04/04/22
Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driverGlobeNewsWire • 03/29/22
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularisGlobeNewsWire • 03/26/22
Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo NodularisPRNewsWire • 03/26/22
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer StudyZacks Investment Research • 03/09/22
WHO Backs Merck's Antiviral Pill For High-Risk Covid Patients But Finds Regeneron's Antibody Cocktail ‘Ineffective' Against OmicronForbes • 03/03/22